Iron and α-synuclein in the substantia nigra of MPTP-treated mice: Effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate

Journal of Molecular Neuroscience

Volumn 24, Issue 3, 2004, Pages 401-416

  Mandel, Silvia ^a   Maor, Gila ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Synuclein; AD; Iron chelator; Iron regulatory protein; MPTP; Neurodegeneration; Neuroprotection; PD; R apomorphine, epigallocatechin 3 gallate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; APOMORPHINE; DOPAMINE; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; IRON; IRON CHELATING AGENT; LIPID; NEUROFILAMENT PROTEIN; NEUROMELANIN; NEUROTOXIN; NITRIC OXIDE; OXIDOPAMINE; POLYPHENOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VK 28; CATECHIN; DRUG DERIVATIVE; FREE RADICAL; NERVE PROTEIN; NEUROPROTECTIVE AGENT; SNCA PROTEIN, MOUSE; SYNUCLEIN; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; IRON CHELATION; LEWY BODY; MALE; MICROGLIA; MORPHOLOGY; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PERMEABILITY; PHOSPHORYLATION; PRIMATE; PROTEIN DEGRADATION; RAT; RODENT; SUBSTANTIA NIGRA; TEA; UBIQUITINATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; METABOLISM; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

PRIMATES; RODENTIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; APOMORPHINE; CATECHIN; DISEASE MODELS, ANIMAL; FREE RADICALS; IRON; IRON CHELATING AGENTS; LEWY BODIES; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; SYNUCLEINS; UBIQUITIN;

EID: 1842621154     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:24:3:401     Document Type: Article

References (100)

1. Aronowski J., Strong R., Shirzadi A., and Grotta J. C. (2003) Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34, 1246-1251.
2. Bar Am O., Amit T., and Youdim M. B. H. (2004a) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett., 355, 169-172.
3. Bar Am O., Yogev-Falach M., Amit T., Sagi Y., and Youdim M. B. H. (2004b) Regulation of protein kinase C by the MAO-B inhibitor anti-Parkinson drug rasagiline and its anti-Alzheimer cholinesterase inhibitor derivatives in vivo. J. Neurochem., 89, 1119-1125.
4. Battaglia G., Busceti C. L., Cuomo L., Giorgi F. S., Orzi F., De Blasi A., et al. (2002a) Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology 42, 367-373.
5. Battaglia G., Gesi M., Lenzi P., Busceti C. L., Soldani P., Orzi F., et al. (2002b) Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann. N. Y. Acad. Sci. 965, 254-266.
6. Ben-Shachar D., Eshel G., Finberg J. P., and Youdim M. B. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
7. Bernardi P., Petronilli V., Di Lisa F., and Forte M. (2001) A mitochondrial perspective on cell death. Trends Biochem. Sci. 26, 112-117.
8. Berra E., Municio M. M., Sanz L., Frutos S., Diaz-Meco M. T., and Moscat J. (1997) Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol. Cell. Biol. 17, 4346-4354.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R., and Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
10. Blum D., Torch S., Nissou M. F., Benabid A. L. and Verna J. M. (2000) Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci. Lett. 283, 193-196.
11. Chase T. N. and Oh J. D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91.
12. Clayton D. F. and George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity neurodegeneration and disease. Trends Neurosci. 21, 249-254.
13. Cory S. and Adams J. M. (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656.
14. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
15. Dempsey E. C., Newton A. C., Mochly-Rosen D., Fields A. P., Reyland M. E., Insel P. A. and Messing R. O. (2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L429-438.
16. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., et al. (2001) Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. 10, 224-253.
17. Elsworth J. D., Deutch A. Y., Redmond D. E., Jr., Sladek J. R., Jr., and Roth R. H. (1990) MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neurosci. Lett. 114, 316-322.
18. Felletschin B., Bauer P., Walter U., Behnke S., Spiegel J., Csoti L, et al. (2003) Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 352, 53-56.
19. Gassen M., Glinka Y., Pinchasi B., and Youdim M. B. H. (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308, 219-225.
20. Gassen M., Gross A., and Youdim M. B. (1998). Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov, Disord, 13, 242-248.
21. Gassen M., Gross A., and Youdim M. B. H. (1999) Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Adv. Neurol. 80, 297-302.
22. Gerlach M., Ben-Shachar D., Riederer P., and Youdim M. B. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807.
23. Grinberg L. N., Newmark H., Kitrossky N., Rahamim E., Chevion M., and Rachmilewitz E. A. (1997) Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem. Pharmacol. 54, 973-978.
24. Group P. S. (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59, 1937-1943.
25. Grunblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., et al. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111, 1435-1463.
26. Grunblatt E., Mandel S., and Youdim M. B. H. (2000) Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann. N. Y. Acad. Sci. 899, 262-273.
27. Grunblatt E., Mandel S., Berkuzki T., and Youdim M. B. H. (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14, 612-618.
28. Grunblatt E., Mandel S., Maor G., and Youdim M. B. H. (2001a) Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77, 146-156.
29. Grunblatt E., Mandel S., Maor G., and Youdim M. B. H. (2001b) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78, 1-12.
30. Gunshin H., Mackenzie B., Berger U. V., Gunshin Y., Romero M. F., Boron W. F., et al. (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388, 482-488.
31. Guo H., Tang Z., Yu Y., Xu L., Jin G., and Zhou J. (2002) Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur. J. Neurosci. 16, 1861-1870.
32. Guo Q., Zhao B., Li M., Shen S., and Xin W. (1996) Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta 1304, 210-222.
33. Hanson E. S. and Leibold E. A. (1999) Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. Gene Expr. 7, 367-376.
34. Hartmann A., Michel P. P., Troadec J. D., Mouatt-Prigent A., Faucheux B. A., Ruberg M., et al. (2001) Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J. Neurochem. 76, 1785-1793.
35. Hashimoto M., Takeda A., Hsu L. J., Takenouchi T., and Masliah E. (1999) Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849-28852.
36. Hassouna I., Wickert H., Zimmermann M., and Gillardon F. (1996) Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment of mice. Neurosci. Lett. 204, 85-88.
37. Hentze M. W. and Kuhn L. C. (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA 93, 8175-8182.
38. Hirsch E. C., Hunot S., Damier P., and Faucheux B. (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44, S115-S120.
39. Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., et al. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94, 7531-7536.
40. Ito K., Nagano-Saito A., Kato T., Arahata Y., Nakamura A., Kawasumi Y., et al. (2002) Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 125, 1358-1365.
41. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
42. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., and Youdim M. B. H. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2, 327-340.
43. Jellinger K. A. (2003) Neuropathological spectrum of synucleinopathies. Mov. Dis. Suppl. 6, S2-S12.
44. Jellinger K. A. (2001) The pathology of Parkinson's disease. Adv. Neurol. 86, 55-72.
45. Jenner P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13, 24-34.
46. Kaasinen V., Nagren K., Hietala J., Oikonen V., Vilkman H., Farde L., et al. (2000) Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54, 1482-1487.
47. Kaur D., Yantiri F., Rajagopalan S., Kumar J., MoJ. Q., Boonplueang R., et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
48. Kim S. and Ponka P. (2000) Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J. Biol. Chem. 275, 6220-6226.
49. Lan J. and Jiang D. H. (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. (Budapest) 104, 469-481.
50. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27, 209-214.
51. Lavedan C. (1998) The synuclein family. Genome Res. 8, 871-880.
52. Leibold E. A., Gahring L. C., and Rogers S. W. (2001) Immunolocalization of iron regulatory protein expression in the murine central nervous system. Histochem. Cell Biol. 115, 195-203.
53. Levites Y., Amit T., Mandel S., and Youdim M. B. H. (2003) Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precusor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17, 952-954.
54. Levites Y., Amit T., Youdim M. B. H., and Mandel S. (2002) Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. 277, 30,574-30,580.
55. Levites Y., Weinreb O., Maor G., Youdim M. B. H., and Mandel S. (2001) Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78, 1073-1082.
56. Linazasoro G. (2002) Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev. Neurother. 2, 403-416.
57. Maher P. (2001) How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21, 2929-2938.
58. Mandel S., Grunblatt E., and Youdim M. B. H. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm. Suppl. 60, 117-124.
59. Mandel S., Grunblatt E., Maor G., and Youdim M. B. H. (2002a) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 27, 1231-1243.
60. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M. B. H. (2003a) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762.
61. Mandel S., Grunblatt E., Royak-Levites Y., Maor G., and Youdim M. B. H. (2002b) Molecular events in dopaminergic neurodegeneration and neuroprotection in MPTP model of parkinson's disease employing cDNA microarray, in Brain DiseasE, Therapeutic Strategies and Repair, Vol. 34, Said, A. C. M., ed., Martin Dunitz, London, pp. 291-298.
62. Mandel S. Weinreb O. Amit T., and Youdim, M.B.H. (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem., 88, 1555-1569.
63. Mandel S., Weinreb O., and Youdim M. B. (2003b) Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol. Sci. 24, 184-191.
64. Maroteaux L. and Scheller R. H. (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11, 335-343.
65. Martin F. L., Williamson S. J. M., Paleologou K. E., Hewitt R., El-Agnaf O. M. A., and Allsop D. (2003) Fe(III)-induced damage in α-synuclein- transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay. J. Neurochem. 87, 620.
66. Masliah E., Iwai A., Mallory M., Ueda K., and Saitoh T. (1996) Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 148, 201-210.
67. Matarredona E. R., Santiago M., Cano J., and Machado A. (1997) Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine. Brain Res. 773, 76-81.
68. McNaught K. S., Belizaire R., Jenner P., Olanow C. W., and Isacson O. (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
69. Merry D. E. and Korsmeyer S. J. (1997) Bcl-2 gene family in the nervous system. Annu. Rev. Neurosci. 20, 245-267.
70. Mori S., Fujitake J., Kuno S., and Sano Y. (1988) Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci. Lett. 90, 57-62.
71. Nagatsu T. (2002) Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. J. Neural Transm. 109, 731-745.
72. Offen D., Beart P. M., Cheung N. S., Pascoe C. J., Hochman A., Gorodin S., et al. (1998) Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA 95, 5789-5794.
73. Ohta M., Mizuta I., Ohta K., Nishimura M., Mizuta E., Hayashi K., and Kuno S. (2000) Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272, 18-22.
74. Olanow C. W. and Youdim M. B. (1996) Iron and neurodegeneration: prospects for neuroprotection, in Neurodegeneration and Neuroprotection in Parkinson's Disease, Olanow, C. W., Jenner, P., and Youdim, M. B., eds., Academic Press, London, pp. 55-69.
75. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer M., and Wolozin B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054.
76. Perry T. L., Yong V. W., Jones K., and Wright J. M. (1986) Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the mouse. Neurosci. Lett. 70, 261-265.
77. Petersen K., Diesen O. F., and Mikkelsen J. D. (1999) Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91, 651-659.
78. Ponka P. (2004) Hereditary causes of distributed iron homeostasis in the central nervous system. Ann. NY Acad. Sci. 1012, 267-281.
79. Ravina B. M., Fagan S. C., Hart R. G., Hovinga C. A., Murphy D. D., Dawson T. M., and Marler J. R. (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60, 1234-1240.
80. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
81. Sagi Y., Weinstock M., and Youdim M. B. (2003) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. 86, 290-297.
82. Salah N., Miller N. J., Paganga G., Tijburg L., Bolwell G. P., and Rice-Evans C. (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys. 322, 339-346.
83. Schneider J. S., Tinker J. P., Van Velson M., Menzaghi F., and Lloyd G. K. (1999) Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 290, 731-739.
84. Seo J. H., Rah J. C., Choi S. H., Shin J. K., Min K., Kim H. S., et al. (2002) α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 5, 5.
85. Shachar D. B., Kahana N., Kampel V., Warshawsky A., and Youdim M. B. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46, 254-263.
86. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M. B. H. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56, 978-982.
87. Temlett J. A., Landsberg J. P., Watt F., Grime G. W. (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62, 134-146.
88. Turnbull S., Tabner B. J., El-Agnaf O. M., Moore S., Davies Y., and Allsop D. (2001) α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30, 1163-1170.
89. Vila M. and Przedborski S. (2003) Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 365-375.
90. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., et al. (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 2837-2842.
91. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.
92. Weinreb O., Mandel S., and Youdim M. B. H. (2003a) cDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J. 17, 935-937.
93. Weinreb O., Mandel S., and Youdim M. B. (2003b) Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin. Ann. N. Y. Acad. Sci. 993, 351-361; discussion, 387-393.
94. Withers G. S., George J. M., Banker G. A., and Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87-94.
95. Yang L., Matthews R. T., Schulz J. B., Klockgether T., Liao A. W., Martinou J. C., et al. (1998) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18, 8145-8152.
96. Yogev-Falach M., Amit T., Bar-Am O., and Youdim M. B. (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17, 2325-2327.
97. Youdim M. B. H. (2003) Rasagiline: an anti-Parkinson drug with neuroprotective activity. Expert Rev. Neurother. 3, 737-749.
98. Youdim M. B. H. and Riederer P. (2004) Iron in the brain, normal and pathological, in Encyclopedia of Neuroscience, Smith, B., and Adelman, G., eds., Elsevier, Amsterdam, in press.
99. Youdim M. B. H., Stephenson G., and Ben-Shachar D. (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators; a lesson from 6-hydroxydopamine and iron chelators desferal and vk-28. Ann. N. Y. Acad. Sci., 1012, 306-325.
100. Zecca L., Youdim M. B., Riederer P., Connor J. R., Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.